2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore lab
2005
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, Investigators F. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal Of Cardiology 2005, 95: 1-7. PMID: 15619385, DOI: 10.1016/j.amjcard.2004.08.054.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationAcute myocardial infarctionPrimary end pointDiabetic patientsNondiabetic patientsPrimary angioplastyDiabetes mellitusStent implantationMyocardial infarctionIschemic target vessel revascularizationEnd pointRoutine stent implantationAbciximab useComposite incidenceReperfusion modalityRoutine stentingAngiographic restenosisVessel revascularizationBalloon angioplastyImproved outcomesPatientsAngioplastyAbciximabDiabetesBeneficial effects
2004
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)
Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, Investigators F. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). The American Journal Of Cardiology 2004, 94: 983-988. PMID: 15476608, DOI: 10.1016/j.amjcard.2004.06.050.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionMajor adverse cardiac eventsAdverse cardiac eventsEarly thrombosisAbciximab usePrimary stentingPrimary angioplastyCardiac eventsBalloon angioplastyMyocardial infarctionBalloon diameterLate Angioplasty Complications (CADILLAC) trialRepeat target vessel revascularizationRepeat coronary angioplastyTarget vessel revascularizationHigh rateControlled AbciximabVessel revascularizationAngiographic morphologyClinical determinantsComplications TrialControl patientsCoronary intervention
2003
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003, 108: 1316-1323. PMID: 12939213, DOI: 10.1161/01.cir.0000087601.45803.86.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyEndpoint DeterminationFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexStentsTreatment OutcomeConceptsComposite end pointTarget vessel revascularizationIschemia-driven target vessel revascularizationPrimary percutaneous coronary interventionAbciximab treatmentPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionCoronary interventionEnd pointPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsInfarct artery reocclusionPrespecified secondary analysisEvent-free survivalFactorial design trialLack of effectAbciximab useAngiographic substudyCADILLAC trialTVR ratesPrimary angioplastyPrimary stentingAngiographic outcomesBenefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The cadillac trial
Kandzari D, Tcheng J, Grines C, Effron M, Fox D, Garcia E, Griffin J, Guagliumi G, Stuckey T, Turco M, Lansky A, Mehran R, Stone G. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The cadillac trial. Journal Of The American College Of Cardiology 2003, 41: 357. DOI: 10.1016/s0735-1097(03)82114-9.Peer-Reviewed Original Research
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting